SynAct Pharma AB (SYNACT.ST)
SEK 9.69
(0.36%)
SEK 9.69
(0.36%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -778 Thousand SEK | 26.88% |
| 2022 | -1.06 Million SEK | -1109.09% |
| 2021 | -88 Thousand SEK | 0.0% |
| 2020 | - SEK | 100.0% |
| 2019 | -338.51 Thousand SEK | -11.51% |
| 2018 | -303.56 Thousand SEK | -20.45% |
| 2017 | -252.01 Thousand SEK | -32.39% |
| 2016 | -190.36 Thousand SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | - SEK | 0.0% |
| 2024 Q2 | - SEK | 0.0% |
| 2024 Q3 | - SEK | 0.0% |
| 2023 Q2 | - SEK | 0.0% |
| 2023 Q4 | - SEK | 0.0% |
| 2023 Q3 | - SEK | 0.0% |
| 2023 FY | -778 Thousand SEK | 26.88% |
| 2023 Q1 | - SEK | 0.0% |
| 2022 Q2 | - SEK | 0.0% |
| 2022 Q4 | - SEK | 0.0% |
| 2022 FY | -1.06 Million SEK | -1109.09% |
| 2022 Q1 | - SEK | 0.0% |
| 2022 Q3 | - SEK | 0.0% |
| 2021 Q4 | - SEK | 0.0% |
| 2021 FY | -88 Thousand SEK | 0.0% |
| 2021 Q3 | - SEK | 0.0% |
| 2021 Q2 | - SEK | 0.0% |
| 2021 Q1 | - SEK | 0.0% |
| 2020 Q3 | - SEK | 0.0% |
| 2020 Q4 | - SEK | 0.0% |
| 2020 FY | - SEK | 100.0% |
| 2020 Q1 | - SEK | 0.0% |
| 2020 Q2 | - SEK | 0.0% |
| 2019 Q2 | - SEK | 0.0% |
| 2019 Q4 | - SEK | 0.0% |
| 2019 FY | -338.51 Thousand SEK | -11.51% |
| 2019 Q1 | - SEK | 0.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 FY | -303.56 Thousand SEK | -20.45% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2017 FY | -252.01 Thousand SEK | -32.39% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 FY | -190.36 Thousand SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 99.516% |
| Ziccum AB (publ) | -23.28 Million SEK | 96.659% |
| Modus Therapeutics Holding AB (publ) | - SEK | Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 100.225% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 101.862% |
| Mendus AB (publ) | 28.48 Million SEK | 102.731% |
| Genovis AB (publ.) | 54 Million SEK | 101.441% |
| Intervacc AB (publ) | -13.79 Million SEK | 94.36% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | 135.836% |
| Active Biotech AB (publ) | -1.67 Million SEK | 53.552% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 107.809% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 102.901% |
| Aptahem AB (publ) | 2.63 Million SEK | 129.574% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | 77.258% |
| Kancera AB (publ) | -1.96 Million SEK | 60.407% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | 1110.39% |
| Fluicell AB (publ) | 1.73 Million SEK | 144.764% |
| Saniona AB (publ) | 11.78 Million SEK | 106.604% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 84.796% |
| Biovica International AB (publ) | 6.87 Million SEK | 111.313% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 96.659% |
| AcouSort AB (publ) | 8.38 Million SEK | 109.274% |
| Xintela AB (publ) | 78 Thousand SEK | 1097.436% |
| Abliva AB (publ) | -35.66 Million SEK | 97.818% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 99.47% |
| Karolinska Development AB (publ) | 2.8 Million SEK | 127.716% |
| OncoZenge AB (publ) | 3000.00 SEK | 26033.333% |
| Amniotics AB (publ) | -1.93 Million SEK | 59.689% |
| 2cureX AB (publ) | -37.48 Million SEK | 97.925% |
| CombiGene AB (publ) | -21.29 Million SEK | 96.346% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | -83.924% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 100.069% |
| Camurus AB (publ) | 1.58 Billion SEK | 100.049% |
| Corline Biomedical AB | 28.38 Million SEK | 102.741% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 99.366% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 97.739% |
| I-Tech AB | 27.56 Million SEK | 102.822% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 101.097% |
| Cyxone AB (publ) | 2.61 Million SEK | 129.797% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | 122.862% |
| Biosergen AB | -456 Thousand SEK | -70.614% |
| Cantargia AB (publ) | -3.45 Million SEK | 77.456% |
| NextCell Pharma AB | -43.74 Million SEK | 98.222% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 91.538% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 106.935% |
| Nanologica AB (publ) | -76 Thousand SEK | -923.684% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | -303.109% |
| Stayble Therapeutics AB (publ) | - SEK | Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | 93.979% |
| Lipum AB (publ) | 53 Thousand SEK | 1567.925% |
| BioInvent International AB (publ) | 71.46 Million SEK | 101.089% |
| Alzinova AB (publ) | 19.87 Million SEK | 103.915% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 102.143% |
| Pila Pharma AB (publ) | 1.46 Million SEK | 153.178% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | -5086.667% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | 146.924% |
| Simris Alg AB (publ) | 2 Million SEK | 138.764% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | 78.268% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 102.198% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | 25.834% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | 124.832% |